 This study will enroll NHL patients with evidence of resolved HBV infection. Eligible subjects must be negative for serum HBV surface antigen HBsAg and positive for at least one of the following in the serum: anti-core antigen anti-HBc, anti-surface antigen anti-HBs, or HBV DNA. Patients who receive at least 1 dose of rituximab-CHOP chemotherapy will be enrolled in to the intent-to-treat population and safety population. Patients who complete at least 1 course of rituximab-CHOP chemotherapy will be enrolled into the per-protocol analysis. The primary and secondary endpoints described in Section 2.1, 2.2, and 2.3 will be included in the per-protocol analysis. 